Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Biosimilars Regulation

Fresenius Nod In EU Adds To Crowded Adalimumab Market

  • News

Executive Summary

Fresenius Kabi has become the latest firm to receive a nod for a European biosimilar rival to Humira, adding to an already crowded biosimilar adalimumab market.

You may also be interested in...



Fresenius Kabi Files EU Pegfilgrastim

Fresenius Kabi’s biosimilar pegfilgrastim rival to Neulasta has been accepted for review by the European Medicines Agency. The firm believes the “milestone” application will pave the way for a 2021 launch.

Biogen Claims Lead Among Adalimumab Biosimilars In Europe

With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.

German Adalimumab Biosimilars Near A Third

Biosimilar adalimumab rivals to AbbVie’s Humira blockbuster continue to take market share in Germany, the latest market data demonstrates.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Tags:
Europe Biosimilars Regulation
UsernamePublicRestriction

Register

GB140060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By